Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Tharos who wrote (4232)	10/22/1997 4:50:00 PM
From: Robert K.	Read Replies (2) \| Respond to of 17367

I added more today at the open and clinched the daily high of 7.75. I really dont care to add at this price but by my best guess we should see 5 to 8 news items in the next 17 trading days. Guess it depends on how prolific Ellen wants to be. I do expect(and hope) that the pending publication of meningococcemia p1/2 results will more or less indicate that its got a great shot at approval in p3. Lots and lots of possible pending news. So I added in anticipation.

To: Tharos who wrote (4232)	10/22/1997 5:13:00 PM
From: Andrew H	Read Replies (2) \| Respond to of 17367

Thanks for the explanation Tharos. I am still not sure what you mean by "conclusive results from FDA," in light of your explanation. Do you mean something like approval from the advisory panel after completion of P3 for meningo? Surely they won't wait to partner hem trauma indication till then, will they. Don't they need a partner to finance P3 hem trauma trials? Don't they want to begin hem trauma trials sooner than later, or are you saying, no they don't? Apologize if I am being dense here. Appreciate your clarifications.